Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

Noushin Farnoud, Kamal Menghrajani, Paola Guglielmelli, Christopher Famulare, Erin McGovern, Giuseppe Gaetano Loscocco, Andriy Derkach, Andrew Dunbar, Naseema Gangat, Vikas Gupta, Andrea Arruda, Taghi Manshouri, Srdan Verstovsek, Andrew Kuykendall, Vincent Ho, Auro Viswabandya, Joachim Deeg, Thomas Monahan, Tania Jain, Jeanne Palmer, Alla Keyzner, Aaron Gerds, Alexandra Gomez-Arteaga, Nikolai Podoltsev, Roni Tamari, Helen Ajufo, Satyajit Kosuri, Haris Ali, Idoroenyi Amanam, Jordan Chervin, Minal Patel, Jesús Gutiérrez-Abril, Sarun Sereewattanawoot, Juan Arango Ossa, Francesco Passamonti, Francesco Maura, Maymona Abdelmagid, Ahmed Abdelrheem, Yassin Bashir, Muhammad Yousuf, Animesh Pardanani, Kapila Viges, David Shoultz, Rick Winneker, Omar Abdel-Wahab, John Mascarenhas, Ronald Hoffman, Ross Levine, Elli Papaemmanuil, Alessandro Vannucchi, Ayalew Tefferi, Raajit Rampal

Blood (2025) 146 (Supplement 1): 2046.

https://doi.org/10.1182/blood-2025-2046

Published: 2025

Journal Articles

Fetal hemoglobin dysregulation in inherited and acquired bone marrow failure syndromes

Blood (2025) 146 (Supplement 1): 6750.

https://doi.org/10.1182/blood-2025-6750

Published: 2025

Journal Articles

DIPSS-R: A revised age-agnostic clinical risk model for chronic phase primary myelofibrosis

Ayalew Tefferi, Alessandro Vannucchi, Yassin Bashir, Ahmed Abdelrheem, Maymona Abdelmagid, Giuseppe Gaetano Loscocco, leonardo Signori, Giulia Borgi, Valentina Boldrini, Kebede Begna, Kaaren Reichard, Rong He, Cinthya Mendoza, Tiziano Barbui, Francesco Passamonti, Animesh Pardanani, Naseema Gangat, Paola Guglielmelli

Blood (2025) 146 (Supplement 1): 84.

https://doi.org/10.1182/blood-2025-84

Published: 2025

Journal Articles

Integrated prognostic model for TP53‑mutated myeloid neoplasms across all myeloid neoplasm subtypes

Blood (2025) 146 (Supplement 1): 2087.

https://doi.org/10.1182/blood-2025-2087

Published: 2025

Journal Articles

Clinical NGS detection of TP53 mutations in chronic phase primary myelofibrosis: Comparative analyses of genotype and prognosis

Blood (2025) 146 (Supplement 1): 3798.

https://doi.org/10.1182/blood-2025-3798

Published: 2025

Journal Articles

Post-FDA approval experience with momelotinib in JAK inhibitor-naïve myelofibrosis: Focus on anemia response and treatment-emergent nephropathy and peripheral neuropathy

Ayalew Tefferi, Maymona Abdelmagid, Jeanne Palmer, Aref Al-Kali, Cecilia Arana Yi, Aasiya Matin, Hassan Alkhateeb, Talha Badar, Yassin Bashir, Kaaren Reichard, Rong He, Animesh Pardanani, Naseema Gangat

Blood (2025) 146 (Supplement 1): 3791.

https://doi.org/10.1182/blood-2025-3791

Published: 2025

Journal Articles

CPX-351 versus venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia: A comparative analysis of outcomes in 600 patients

Blood (2025) 146 (Supplement 1): 1602.

https://doi.org/10.1182/blood-2025-1602

Published: 2025

Journal Articles

MAPS-R: International consensus classification-guided revision of the mayo alliance prognostic system for systemic mastocytosis

Ayalew Tefferi, Fnu Aperna, Mahesh Kumar, Maymona Abdelmagid, Joseph Butterfield, Thanai Pongdee, Cecilia Arana Yi, Daniel Arber, Attilio Orazi, Dong Chen, Kaaren Reichard, Naseema Gangat, Animesh Pardanani

Blood (2025) 146 (Supplement 1): 2017.

https://doi.org/10.1182/blood-2025-2017

Published: 2025

Journal Articles

BLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia

Blood (2025) 146 (7): 874–886.

https://doi.org/10.1182/blood.2024027170

Published: 2025

Includes: Supplemental data

Journal Articles

Monocytosis Is an Independent Risk Factor for Survival in Essential Thrombocythemia - a Revised Triple-a Prognostic Score (AAA+A) Based on Age and Absolute Monocyte, Neutrophil, and Lymphocyte Counts

Ayalew Tefferi, Giuseppe Gaetano Gaetano Loscocco, Maymona Abdelmagid, Animesh D. Pardanani, Kebede Begna, Mrinal M. Patnaik, Natasha Szuber, Alessandra Carobbio, Tiziano Barbui, Kaaren K. Reichard, Paola Guglielmelli, Naseema Gangat, Alessandro M. Vannucchi

Blood (2024) 144 (Supplement 1): 3169.

https://doi.org/10.1182/blood-2024-193907

Published: 2024

Journal Articles

Pacritinib Therapy for JAK2 Inhibitor-Naïve or -Experienced Patients with Myelofibrosis: Mayo Clinic Series of 60 Consecutive Patients Treated Outside of Clinical Trials

Maymona Abdelmagid, Jeanne Palmer, Aref Al-Kali, Mehrdad Hefazi, James M. Foran, Kebede Begna, Cecilia Y. Arana Yi, Animesh D. Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2024) 144 (Supplement 1): 1798.

https://doi.org/10.1182/blood-2024-198757

Published: 2024

Journal Articles

The Mutational Landscape of Polycythemia Vera and Its Phenotypic and Prognostic Correlates

Masooma S Rana, Moazah Iftikhar, Yamna Jadoon, Maymona Abdelmagid, David Viswanatha, Rong He, Kaaren K. Reichard, Animesh D. Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2024) 144 (Supplement 1): 1797.

https://doi.org/10.1182/blood-2024-193119

Published: 2024

Journal Articles

Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Blood (2024) 144 (Supplement 1): 4247.

https://doi.org/10.1182/blood-2024-204114

Published: 2024

Journal Articles

Polycythemia Vera Vs. JAK2 Mutated or Wild-Type Essential Thrombocythemia: Clinical and Molecular Comparisons and Long-Term Outcome Among 2,010 Patients

Giuseppe Gaetano Loscocco, Moazah Iftikhar, Masooma S Rana, Omer Karrar, Maymona Abdelmagid, Animesh D. Pardanani, Kebede Begna, Natasha Szuber, Tiziano Barbui, Paola Guglielmelli, Alessandro Maria Vannucchi, Cinthya Zepeda Mendoza, Kaaren K. Reichard, Rong He, Ayalew Tefferi, Naseema Gangat

Blood (2024) 144 (Supplement 1): 6621.

https://doi.org/10.1182/blood-2024-193373

Published: 2024

Journal Articles

TP53 mutations and Complex Karyotype in Newly-Diagnosed Blast/Accelerated Phase MPN Are Associated with Ephemeral Response to Treatment with Venetoclax + HMA and Poor Survival

Blood (2024) 144 (Supplement 1): 6657.

https://doi.org/10.1182/blood-2024-193917

Published: 2024

Journal Articles

Cytogenetic Abnormalities in Polycythemia Vera: Phenotypic Correlates and Prognostic Relevance in 669 Informative Cases

Moazah Iftikhar, Masooma S Rana, Yamna Jadoon, Maymona Abdelmagid, Kaaren K. Reichard, Cinthya Zepeda Mendoza, Animesh D. Pardanani, Ayalew Tefferi, Naseema Gangat

Blood (2024) 144 (Supplement 1): 3176.

https://doi.org/10.1182/blood-2024-193120

Published: 2024

Journal Articles

TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance

Blood (2024) 144 (Supplement 1): 244.

https://doi.org/10.1182/blood-2024-210251

Published: 2024

Journal Articles

Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Blood (2024) 144 (Supplement 1): 2852.

https://doi.org/10.1182/blood-2024-209015

Published: 2024

Journal Articles

Basophilia in Polycythemia Vera Is Associated with an Increased Risk of Leukemic and Myelofibrotic Transformation

Mahlet Siraga, Maymona Abdelmagid, Moazah Iftikhar, Masooma S Rana, Kebede Begna, Kaaren K. Reichard, Rong He, Cinthya Zepeda Mendoza, Ronald S Go, Animesh D. Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2024) 144 (Supplement 1): 6625.

https://doi.org/10.1182/blood-2024-198840

Published: 2024

Journal Articles

CALR mutation burden in essential thrombocythemia and disease outcome

Paola Guglielmelli, Natasha Szuber, Naseema Gangat, Giulio Capecchi, Chiara Maccari, Michaël Harnois, Omer Karrar, Maymona Abdelmagid, Manjola Balliu, Elena Nacca, Alessandro Atanasio, Ilaria Sestini, Audrey Désilets, Giuseppe Gaetano Loscocco, Giada Rotunno, Lambert Busque, Ayalew Tefferi, Alessandro Maria Vannucchi

Blood (2024) 143 (13): 1310–1314.

https://doi.org/10.1182/blood.2023023428

Published: 2024

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

Fetal hemoglobin dysregulation in inherited and acquired bone marrow failure syndromes

DIPSS-R: A revised age-agnostic clinical risk model for chronic phase primary myelofibrosis

Integrated prognostic model for TP53‑mutated myeloid neoplasms across all myeloid neoplasm subtypes

Clinical NGS detection of TP53 mutations in chronic phase primary myelofibrosis: Comparative analyses of genotype and prognosis

Post-FDA approval experience with momelotinib in JAK inhibitor-naïve myelofibrosis: Focus on anemia response and treatment-emergent nephropathy and peripheral neuropathy

CPX-351 versus venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia: A comparative analysis of outcomes in 600 patients

MAPS-R: International consensus classification-guided revision of the mayo alliance prognostic system for systemic mastocytosis

BLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia

Monocytosis Is an Independent Risk Factor for Survival in Essential Thrombocythemia - a Revised Triple-a Prognostic Score (AAA+A) Based on Age and Absolute Monocyte, Neutrophil, and Lymphocyte Counts

Pacritinib Therapy for JAK2 Inhibitor-Naïve or -Experienced Patients with Myelofibrosis: Mayo Clinic Series of 60 Consecutive Patients Treated Outside of Clinical Trials

The Mutational Landscape of Polycythemia Vera and Its Phenotypic and Prognostic Correlates

Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Polycythemia Vera Vs. JAK2 Mutated or Wild-Type Essential Thrombocythemia: Clinical and Molecular Comparisons and Long-Term Outcome Among 2,010 Patients

TP53 mutations and Complex Karyotype in Newly-Diagnosed Blast/Accelerated Phase MPN Are Associated with Ephemeral Response to Treatment with Venetoclax + HMA and Poor Survival

Cytogenetic Abnormalities in Polycythemia Vera: Phenotypic Correlates and Prognostic Relevance in 669 Informative Cases

TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance

Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Basophilia in Polycythemia Vera Is Associated with an Increased Risk of Leukemic and Myelofibrotic Transformation

CALR mutation burden in essential thrombocythemia and disease outcome

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only